Bei Jing Shang Bao·2025-10-27 12:33Core Viewpoint - 康希诺 reported a significant increase in revenue and a return to profitability in the first three quarters of 2025, driven by strong market performance of its innovative vaccine products and enhanced government support [1] Financial Performance - The company achieved an operating income of 693 million yuan, representing a year-on-year growth of 22.13% [1] - The net profit attributable to the company was 14.44 million yuan, marking a turnaround from previous losses [1] Product and Market Development - 曼海欣, as one of the only four-valent meningococcal conjugate vaccines in China, has shown strong market performance and increasing market share [1] - The growth in sales revenue contributed to the year-on-year increase in operating income from the beginning of the year to the reporting period [1] Research and Development Support - The company has accelerated its R&D projects and international collaborations, leading to increased government grants and international funding, resulting in a year-on-year increase of 233.63% in recognized other income [1] Profitability and Cost Management - The overall gross profit margin for the reporting period was 80.67%, an increase of 6.47 percentage points year-on-year [1] - The company has implemented cost reduction and efficiency improvement measures, achieving savings in multiple expense categories during the reporting period [1]